163 related articles for article (PubMed ID: 37019987)
1. 2-[
Vogsen M; Naghavi-Behzad M; Harbo FG; Jakobsen NM; Gerke O; Asmussen JT; Nissen HJ; Dahlsgaard-Wallenius SE; Braad PE; Jensen JD; Ewertz M; Hildebrandt MG
Sci Rep; 2023 Apr; 13(1):5552. PubMed ID: 37019987
[TBL] [Abstract][Full Text] [Related]
2. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing
Vogsen M; Harbo F; Jakobsen NM; Nissen HJ; Dahlsgaard-Wallenius SE; Gerke O; Jensen JD; Asmussen JT; Jylling AMB; Braad PE; Vach W; Ewertz M; Hildebrandt MG
J Nucl Med; 2023 Mar; 64(3):355-361. PubMed ID: 36207136
[TBL] [Abstract][Full Text] [Related]
3. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
Riedl CC; Pinker K; Ulaner GA; Ong LT; Baltzer P; Jochelson MS; McArthur HL; Gönen M; Dickler M; Weber WA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1428-1437. PubMed ID: 28462446
[TBL] [Abstract][Full Text] [Related]
4. Prospective comparison of early interim
Su TP; Huang JS; Chang PH; Lui KW; Hsieh JC; Ng SH; Chan SC
BMC Cancer; 2021 Aug; 21(1):908. PubMed ID: 34376155
[TBL] [Abstract][Full Text] [Related]
5. Clinical Value of
Hynninen J; Laasik M; Vallius T; Kemppainen J; Grönroos S; Virtanen J; Casado J; Hautaniemi S; Grenman S; Seppänen M; Auranen A
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):507-514. PubMed ID: 29753662
[TBL] [Abstract][Full Text] [Related]
6.
Makhlin I; Korhonen KE; Martin ML; Gillman J; Schubert E; Pantel AR; Mankoff DA; Clark AS
Radiol Imaging Cancer; 2022 Nov; 4(6):e220032. PubMed ID: 36269154
[TBL] [Abstract][Full Text] [Related]
7. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
8. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
9. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of 2-[
Naghavi-Behzad M; Gerke O; Kodahl AR; Vogsen M; Asmussen JT; Weber W; Hildebrandt MG; Kidholm K
Sci Rep; 2023 Sep; 13(1):16315. PubMed ID: 37770525
[TBL] [Abstract][Full Text] [Related]
11. Prospective Study of Serial
Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM
J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233
[TBL] [Abstract][Full Text] [Related]
12. A role of FDG-PET/CT for response evaluation in metastatic breast cancer?
Hildebrandt MG; Naghavi-Behzad M; Vogsen M
Semin Nucl Med; 2022 Sep; 52(5):520-530. PubMed ID: 35525631
[TBL] [Abstract][Full Text] [Related]
13. Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT.
Naghavi-Behzad M; Vogsen M; Vester RM; Olsen MMB; Oltmann H; Braad PE; Asmussen JT; Gerke O; Vach W; Kidholm K; Kodahl AR; Weber W; Hildebrandt MG
Br J Cancer; 2022 May; 126(9):1271-1279. PubMed ID: 35013575
[TBL] [Abstract][Full Text] [Related]
14. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
15. Comparison of prognostic value of different metabolic response criteria determined by PET/CT in patients with metastatic breast cancer under CDK 4/6 inhibitor treatment.
Önner H; Eren OÖ; Körez MK; Yilmaz F; Kara Gedik G
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):319-324. PubMed ID: 37030597
[TBL] [Abstract][Full Text] [Related]
16. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review.
Helland F; Hallin Henriksen M; Gerke O; Vogsen M; Høilund-Carlsen PF; Hildebrandt MG
Diagnostics (Basel); 2019 Aug; 9(3):. PubMed ID: 31461923
[TBL] [Abstract][Full Text] [Related]
18. Predicting tumor response and outcome of second-look surgery with
Aide N; Fauchille P; Coquan E; Ferron G; Combe P; Meunier J; Alexandre J; Berton D; Leary A; De Rauglaudre G; Bonichon N; Pujade Lauraine E; Joly F
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1998-2008. PubMed ID: 33221969
[TBL] [Abstract][Full Text] [Related]
19. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
20. Comparison Between
Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]